-
Mashup Score: 0
The addition of ramucirumab to pembrolizumab elicited an encouraging response rate when used in the frontline treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2
Eric K. Singhi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the rationale and results…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0The impact of the COVID-19 pandemic on cancer care and research - 2 year(s) ago
Kannan Natarajan, PhD, Pfizer, Brooklyn, NY, shares his thoughts on the impact of the COVID-19 pandemic in oncology. Restricted access…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Alexander Kamb, PhD, A2 Biotherapeutics, Agoura Hills, CA, discusses A2 Biotherapeutics’ ongoing work in developing cell therapies using antigenic targets…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Mehmet Altan on Solid Tumors Interim Safety and Efficacy Results on NKTR-255 Plus Cetuximab - The ASCO Post - 2 year(s) ago
SITC 2021 Mehmet Altan, MD, of The University of Texas MD Anderson Cancer Center, discusses findings from a phase Ib dose-escalation study, which showed early evidence of activity for NKTR-255, an investigational IL-15 receptor agonist, plus cetuximab in patients with solid tumors. Treatment appeared to lead to expansion and proliferation of NK and…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Afaf Abed, MBBS, FRACP, Fiona Stanley Hospital, Murdoch, Australia, discusses the implications of using the pre-treatment T-Cell receptor (TCR) repertoire…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3Hannah Dzimitrowicz on COVID-19 Vaccination in Patients With Cancer Receiving Immune Checkpoint Inhibitors - The ASCO Post - 2 year(s) ago
SITC 2021 Hannah E. Dzimitrowicz, MD, of Duke Cancer Center, discusses study results showing that in patients with melanoma and renal cell cancer receiving immune checkpoint inhibitor therapy, the COVID-19 vaccination appears to be well tolerated and safe. A higher rate of post-vaccination symptoms reported in these patients is likely…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0The future of cell therapy in solid tumors - 2 year(s) ago
Alexander Kamb, PhD, A2 Biotherapeutics, Agoura Hills, CA, talks on the potential of cell therapies for solid tumors. Cell therapies…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3Stephanie Schmidt on NSCLC The Immunomodulatory Impact of Neoadjuvant Chemotherapy and Immune-Based Treatments - The ASCO Post - 2 year(s) ago
SITC 2021 Stephanie T. Schmidt, PhD, of The University of Texas MD Anderson Cancer Center, discusses the first integrated examination of the immunomodulatory effects of neoadjuvant chemotherapy, nivolumab, and nivolumab plus chemotherapy in resected non–small cell lung cancer (Abstract 962). Related Videos …
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0PY159: An anti-TREM-1 antibody and the next steps - 2 year(s) ago
Nadine Jahchan, BSc, PhD, Pionyr Immunotherapeutics, San Francisco, CA, describes the development of PY159, an anti-triggering receptor expressed on myeloid…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Ramucirumab/Pembrolizumab Produces Encouraging ORR in Recurrent or Metastatic HNSCC @WUSTLmed @sitcancer #SITC21 #hncsm #oncology https://t.co/7xxHLoEWjf